Obbligazione Barclay PLC 4.25% ( US06738JHR86 ) in USD

Barclay PLC

100.715 USD ⇌

Regno Unito

US06738JHR86 ( in USD )

4.25% per anno ( pagato 2 volte l'anno)

30/09/2025

Prospetto opuscolo dell'obbligazione Barclays PLC US06738JHR86 en USD 4.25%, scadenza 30/09/2025

1 000 USD

1 062 000 USD

06738JHR8

A+ ( Upper medium grade - Investment-grade )

A1 ( Upper medium grade - Investment-grade )

30/09/2025 ( In 129 giorni )

Barclays PLC è una banca multinazionale britannica che offre una vasta gamma di servizi finanziari a clienti privati, aziende e istituzioni in tutto il mondo.

The Obbligazione issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06738JHR86, pays a coupon of 4.25% per year.
The coupons are paid 2 times per year and the Obbligazione maturity is 30/09/2025

The Obbligazione issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06738JHR86, was rated A1 ( Upper medium grade - Investment-grade ) by Moody's credit rating agency.

The Obbligazione issued by Barclay PLC ( United Kingdom ) , in USD, with the ISIN code US06738JHR86, was rated A+ ( Upper medium grade - Investment-grade ) by Standard & Poor's ( S&P ) credit rating agency.

Pricing Supplement - USD 15 YR USMTN
Page 1 of 11
424B2 1 d424b2.htm PRICING SUPPLEMENT - USD 15 YR USMTN
CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities Offered

Maximum Aggregate Offering Price
Amount of Registration Fee(1)
Global Medium-Term Notes, Series A

$1,062,000
$75.72
(1) Calculated in accordance with Rule 457(r) of the Securities Act of 1933.
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 2 of 11
Pricing Supplement dated September 27, 2010
Filed Pursuant to Rule 424(b)(2)
(To Prospectus dated August 31, 2010 and
Registration No. 333-169119
the Prospectus Supplement dated August 31, 2010)
U
S
P
Ite·pF
B
LS
r
Oon
M
S
De

nF
nau
htoi $1
TEP
ssue
the
Notes
aIN:
Eu
qual
o
The
hr r
Dated
peai06
rpU
Pt
eari
iginal
ci
terest
turity
U
o
Othe
terest
ddr
o:
yable
rvivor
er
sting: 2
P
incipal
Londo
eaci
th
siness (
ght4
hn
The's000
FIXE
A
ce:
nIa
f
of
to
D
ttlement: 10
Issue
ncludin
Rate
Date:
nominatio
Rate:r
ermitted
a
The r
Oy
D·
00%
nte
Period
itional r
nte
Period:
inal
the
d
mitted
N D
0%
DgS
ns:F
Payment
d
C o
ears
b
TC; R
mount:
Type:
M)r
per
estDo
The
will
ption:
exerci
ollar
onv
otes AT
U
Ser
ate:
anyF
Ba
Pe
nib
se
dollar
etails
w i
See
reditworthiness
p
S06738JHR86
eac
re
InterestaE
S$1
inim
illo
h
ates:
gin
Upon
eneficia
this
ook NOT
es:
ixed
iod062
fI
verl
e G
eptemberB
R
um
nnumc
y
nitial
ention:nI
oo
mount
not lo
a
rincip
nte
on ral
30
de
M
Period
of
mount
try;
be ES
0
tea 0
ptember
est
30th
wne
option
of
regarding 0
bal3
Or
to
nd
requestra DU
I
M
0
clays
prot
2025
P
we
onthlyf
nterest
will
of
total
n
he e
B
rM
P
in
by
ill
Following
listed E
ssue
d
iginal
iod
mmencing
end
the
be
on S
r
xer:
2010
ank
ectionc
o
indivaEPT
cludeaiB
iumP
eriod
Np
nominationso
n
Qu
Transferaba
archn
Un ar
CUSIP:of
Sr
sub
le
y te
w
the
j
ises
Survivor' E
LC
Trader
and
ill
otes
duals
U lI
but
ectMBER
clays
Term
Principa
Dy
Se
by
e x
to
O l
rovided
uthorized:
adjusted B
US$1P
Thea
ate:

begin
all a
Notes
Nt
06738JH
00
mmencing
eptember
provido
o
ntereste
xercise
ption 30
nk
rote
m
R
clude
Day8
0n
30
nPdbs P
S
otes
ao
Semi
eptemberasy
ee
C
securities2025
LC
eries
ction
ar
represe
holdersr
ndAc
then
a"e
aturity
a
ndef
o
uch t
aymen
M
of
D
ount A
P
2019
2021
2023
2024te ercentage:
not
September
er
N 2
integr
to
tative
xcha either
dep
7
holder
Con e
al
the
nnually
o
otes
thesev nds
2010
includefomul
O
but
Date
aturity
ngetN
f t A
mmencing
for
he
scription
or o
thet
Date
were
otesI
on
riginn
O
hese
f
ention: fa
heSyou
directly
the
tiples
l
in I
excludi
M
benefi
quotat a
of
ng
nnually
riginahold
or
bility
acquire
anyU
ssue
archl
Notes
ion I
cial
di
30/360sD
Sept
the
30
bn
urvivor y
'as t
preceding he
of
S$1
ate
M
ssueI
owner
ny
O
ystem Notes
indirectly
Bt
D
calendar a
000
o
ember
2011but
aturitf
y 3
y
ate
nteret
ption 0
s D
and
athe
ear
" ; t
an
P
calenda o
rclays
ate
e
nd
deceased
ar
bel m
thereafte
nd
yo t
erio aturity
obliga
Bank
r
excludi
2021
2023
2024he
nding
endd
ea
w o
Notesa
r tion
B
ng
the
nnd
w i
int
onee
benefici yo
o
PLC
but
wal ft
Sept
the
endillua
o
usiness
rest
exsr
M
o w
ny
D
nteresta
n
own ill
ay:
ember
rte
clude
repay
er receiv
third
atisfy
but
3
ate
pe
aturitt
a 0
pr
yl p
its
er
aD
the f
hose e
nnu
ate
east at
arty
New
2019m
irst
exclude
Nsix least
and
Ythe
annum
w
otes
m a
orki
illn 100%
ny
obligations
willas
be
Interest
ext
prior
onthst t
bef h
nterest
o
prt of
ey
r
equ
equal
iora
equt
he yo
payment
co
atel
ollowit
o:
Payment
o ur
ptto
me
er
o:
6D
nghe pri
b
45 e
ate
Maturi n
due
00%
Inte
ty ci
m
25%
50%
00%
Ea
res
date pal
ade
annump
per
tof e
p
chP
Dater
aa
th s
oyeubjec
n
willa
subt
mrh
nn
se
folloe
be
nnumnt
w
equ t
um
equent
ing
est
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 3 of 11
P
(cb[r
P
T1
m
T ice
e
or
o)a
h
Ge
We N
tal
B
y r
ingt
No
ot
$
ar
et
ma
marketut
iminalP
e
1y ublic
100%
062
clays
ain
esu
sed a
mmission
sei
RAPHIC C
ll
will
resalen a Agent
1
000
apital
or
has
offense
this a
notp '
$18I
be s
75%5
market
APPEARS C
98
8
nc
pricing
transaction ommi
5
ortion
pproveds
H 25%
$
listed1
will
ofr
in
resale t
on
d ssion
043
receive
he
ERE] se
any
upplement
any N (1)
415
Ui S
n
otes t
transactionP
comm
isapproved
af roce
o
he fi
ter t
n eds
commissi
issions
he o
securities
hese
itialir t
onsrso
eseB
ale
ini arclay
from
use a
of
tial the
lls or
xchange
curities
Naleso B
a
orr
otesU ank
Issuer
de
I t
n P
nless LC
equal
portion o
addit
w fi
e t
quotation o
ts
ermined
on
or 1
t 75%
hese
ystem
hat
our t of
N
his p
Barclays
agent the
i
p
either r
ricingincipal
commissions
the
Capitalto
nforms S
I ec
nc
you amount
pay s
or elling
urities
supplement a
is of
t c
nd
another
otherwise it
oEh
nxfet note
ruthful o
our
he r s
cessions
change
co
conf or
m $17
fee
affiliates s
pletem50
to
A
ay
irmation oper
Commission
ny
use
f s $
othert1
ale d
nor 000
any
represe
hist pn
ri
his princi
ealers
state
tation
cing
p
pal
t
ricingo
supp
s am
the
le ount
securities
contr
ment
upplemen and
ary
int isis a
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 4 of 11
The Notes constitute our direct, unconditional, unsecured and unsubordinated obligations and are not deposit
liabilities of Barclays Bank PLC and are not insured by the U.S. Federal Deposit Insurance Corporation or any other
governmental agency of the United States, the United Kingdom or any other jurisdiction.
Investing in the Notes involves a number of risks. See "Risk Factors" beginning on page S-5 of the prospectus
supplement and "Selected Risk Factors" below. We urge you to consult your investment, legal, tax, accounting and
other advisers and to invest in the Notes only after you and your advisors have carefully considered the suitability of
an investment in the Notes in light of your particular circumstances.
Barclays Bank PLC has filed a registration statement (including a prospectus) with the SEC for the offering to which
this pricing supplement relates. Before you invest, you should read the prospectus dated August 31, 2010, the
prospectus supplement dated August 31, 2010, and other documents Barclays Bank PLC has filed with the SEC for
more complete information about Barclays Bank PLC. and this offering. Buyers should rely upon this pricing
supplement, the prospectus, the prospectus supplement, and any relevant free writing prospectus for complete details.
You may get these documents and other documents Barclays Bank PLC has filed for free by visiting EDGAR on the
SEC website at www.sec.gov, and you may also access the prospectus and prospectus supplement through the links
below:

·
Prospectus dated August 31, 2010:
http://www.sec.gov/Archives/edgar/data/312070/000119312510201448/df3asr.htm

·
Prospectus Supplement dated August 31, 2010:
http://www.sec.gov/Archives/edgar/data/312070/000119312510201604/d424b3.htm
Our Central Index Key, or CIK, on the SEC website is 1-10257.
Alternatively, Barclays Capital Inc. or any agent or dealer participating in this offering will arrange to send you this
pricing supplement, the prospectus, the prospectus supplement and any relevant free writing prospectus if you
request it by calling your Barclays Capital Inc. sales representative, such dealer or 1-888-227-2275 (Extension 2-3430).
A copy of the prospectus may be obtained from Barclays Capital Inc., 745 Seventh Avenue--Attn: US InvSol
Support, New York, NY 10019.
You may revoke your offer to purchase the Notes at any time prior to the time at which we accept such offer by notifying the
applicable agent. We reserve the right to change the terms of, or reject any offer to purchase the Notes prior to their issuance.
In the event of any changes to the terms of the Notes, we will notify you and you will be asked to accept such changes in
connection with your purchase. You may also choose to reject such changes in which case we may reject your offer to
purchase.
As used in this term sheet, the "Company," "we," "us," or "our" refers to Barclays Bank PLC.
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 5 of 11
SELECTED RISK FACTORS
An investment in the Notes involves significant risks. You should read the risks summarized below in connection with,
and the risks summarized below are qualified by reference to, the risks described in more detail in the "Risk Factors"
section beginning on page S-5 of the prospectus supplement. We urge you to consult your investment, legal, tax,
accounting and other advisers and to invest in the Notes only after you and your advisors have carefully considered
the suitability of an investment in the Notes in light of your particular circumstances.

·
Issuer Credit Risk-- The Notes are our unsecured debt obligations, and are not, either directly or indirectly, an
obligation of any third party. Any payment to be made on the Notes, including any principal protection provided at
maturity, depends on our ability to satisfy our obligations as they come due. As a result, the actual and perceived

creditworthiness of Barclays Bank PLC may affect the market value of the Notes and, in the event we were to
default on our obligations, you may not receive the principal protection or any other amounts owed to you under
the terms of the Notes.

·
Certain Built-In Costs Are Likely to Adversely Affect the Value of the Notes Prior to Maturity--Although
you will not receive less than the principal amount of the Notes if you hold the Notes to maturity, the Original Issue
Price of the Notes includes the agent's commission and the cost of hedging our obligations under the Notes through

one or more of our affiliates. As a result, assuming no change in market conditions or any other relevant factor, the
price, if any, at which Barclays Capital Inc. and other affiliates of Barclays Bank PLC will be willing to purchase
Notes from you in secondary market transactions may be lower than the Original Issue Price, and any sale prior to
the Maturity Date could result in a substantial loss to you.

·
Potential Conflicts--We and our affiliates play a variety of roles in connection with the issuance of the Notes,

including hedging our obligations under the Notes. In performing these duties, the economic interests of our
affiliates of ours are potentially adverse to your interests as an investor in the Notes.
In addition, Barclays Wealth, the wealth management division of Barclays Capital Inc., may arrange for the sale of
the Notes to certain of its clients. In doing so, Barclays Wealth will be acting as agent for Barclays Bank PLC and
may receive compensation from Barclays Bank PLC in the form of discounts and commissions. The role of
Barclays Wealth as a provider of certain services to such customers and as agent for Barclays Bank PLC in
connection with the distribution of the Notes to investors may create a potential conflict of interest, which may be
adverse to such clients. Barclays Wealth is not acting as your agent or investment adviser, and is not representing
you in any capacity with respect to any purchase of Notes by you. Barclays Wealth is acting solely as agent for
Barclays Bank PLC. If you are considering whether to invest in the Notes through Barclays Wealth, we strongly
urge you to seek independent financial and investment advice to assess the merits of such investment.

·
Lack of Liquidity--The Notes will not be listed on any securities exchange. Barclays Capital Inc. and other
affiliates of Barclays Bank PLC intend to make a secondary market for the Notes but are not required to do so, and
may discontinue any such secondary market making at any time, without notice. Even if there is a secondary
market, it may not provide enough liquidity to allow you to trade or sell the Notes easily. Because other dealers are

not likely to make a secondary market for the Notes, the price at which you may be able to trade your Notes is
likely to depend on the price, if any, at which Barclays Capital Inc. and other affiliates of Barclays Bank PLC are
willing to buy the Notes. The Notes are not designed to be short-term trading instruments. Accordingly, you should
be able and willing to hold your Notes to maturity.

·
Many Economic and Market Factors Will Impact the Value of the Notes--The value of the Notes will be

affected by a number of economic and market factors that may either offset or magnify each other, including:

·
the time to maturity of the Notes;

·
interest and yield rates in the market generally;

·
a variety of economic, financial, political, regulatory or judicial events; and

·
our creditworthiness, including actual or anticipated downgrades in our credit ratings.

PS1
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 6 of 11
DESCRIPTION OF SURVIVOR'S OPTION
Upon request by the authorized representative of the beneficial owner of the Notes, Barclays Bank PLC will repay those
Notes prior to the Maturity Date following the death of the beneficial owner of the Notes (the "Survivor's Option"),
provided such Notes were acquired by the deceased beneficial owner at least six months prior to the date of the request. Upon
the valid exercise of the Survivor's Option and the proper tender of the Notes for repayment, Barclays Bank PLC will repay
such Notes, in whole or in part, at a price equal to 100% of the principal amount of the deceased beneficial owner's beneficial
interest in the Notes plus accrued and unpaid interest to the date of repayment. For purposes of this section, a beneficial
owner of Notes is a person who has the right, immediately prior to such person's death, to receive the proceeds from the
disposition of such Notes, as well as the right to receive payment of the principal of the Notes.
To be valid, the Survivor's Option must be exercised by or on behalf of the person who has authority to act on behalf of the
deceased beneficial owner of the Notes under the laws of the applicable jurisdiction (including, without limitation, the
personal representative of or the executor of the estate of the deceased beneficial owner or the surviving joint owner with the
deceased beneficial owner).
The death of a person holding a beneficial ownership interest in the Notes: (1) with any person in a joint tenancy with right of
survivorship; or (2) with his or her spouse in tenancy by the entirety, tenancy in common, as community property or in any
other joint ownership arrangement, will be deemed the death of a beneficial owner of those Notes, and the entire principal
amount of the Notes held in this manner will be subject to repayment by Barclays Bank PLC upon request. However, the
death of a person holding a beneficial ownership interest in Notes as tenant in common with a person other than his or her
spouse will be deemed the death of a beneficial owner only with respect to such deceased person's interest in the Notes, and
only the deceased beneficial owner's percentage interest in the principal amount of the Notes will be subject to repayment.
If the ownership interest in the Notes is held by a nominee for a beneficial owner or by a custodian under a Uniform Gifts to
Minors Act or Uniform Transfer to Minors Act, or by a trustee of a trust that is wholly revocable by the beneficial owner, or
by a guardian or committee for a beneficial owner, the death of the beneficial owner of the Notes will constitute death of the
beneficial owner for purposes of the Survivor's Option, if the beneficial ownership interest can be established to the
satisfaction of Barclays Bank PLC. In these cases, the death of the nominee, custodian, trustee, guardian or committee will
not be deemed the death of the beneficial owner of the Notes for purposes of the Survivor's Option.
Barclays Bank PLC has the discretionary right to limit the aggregate principal amount of the Notes as to which exercises of
the Survivor's Option will be accepted by it from all authorized representatives of deceased beneficial owners in any calendar
year, to an amount equal to 2.0% of the aggregate amount of the Notes, outstanding as of the end of the most recent calendar
year.
Barclays Bank PLC also has the discretionary right to limit to $250,000 the aggregate principal amount of Notes as to which
exercises of the Survivor's Option will be accepted by Barclays Bank PLC from the authorized representative for any
individual deceased beneficial owner of such notes in any calendar year. In addition, Barclays Bank PLC will not permit the
exercise of the Survivor's Option (a) for a principal amount less than $1,000, or (b) if such exercise will result in a beneficial
ownership interest in a note with a principal amount of less than $1,000 outstanding.
An otherwise valid election to exercise the Survivor's Option may not be withdrawn. Elections to exercise the Survivor's
Option will be accepted in the order that they are received and approved by Barclays Bank PLC, except for any election the
acceptance of which would contravene any of the limitations described above. Notes accepted for repayment through the
exercise of the Survivor's Option will be repaid on the first Interest Payment Date that occurs 60 or more calendar days after
the date of the acceptance and approval by Barclays Bank PLC. Each tendered Note that is not accepted in any calendar year
due to the application of any of the limitations described in the preceding paragraph will be deemed to be tendered in the
following calendar year in the order in which all such Notes were originally tendered. If a Note tendered through a valid
exercise of the Survivor's Option is not accepted by Barclays Bank PLC, the trustee, upon receipt of a valid written
instruction from Barclays Bank PLC or its agent, will deliver a notice to the registered holder that states the reason that Note
has not been accepted for repayment.
Because the Notes will be issued in book-entry form (except in very limited circumstances), DTC or its nominee will be
treated as the holder of the Notes, will be the only entity that receives notices from Barclays Bank PLC (or the trustee) and,
on behalf of the deceased beneficial owner's authorized representative, will be the only entity that can exercise the Survivor's
Option for such Notes. To obtain repayment of the Notes pursuant to exercise of the Survivor's Option, the deceased
beneficial owner's authorized representative must provide the following items to the broker or other entity through which the
beneficial interest in the Notes is held by the deceased beneficial owner:

·
appropriate evidence satisfactory to Barclays Bank PLC that:

(1)
the deceased was the beneficial owner of the Notes at the time of death and his or her interest in the Notes
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 7 of 11

was acquired by the deceased beneficial owner at least six months prior to the request for repayment,

(2)
the death of the beneficial owner has occurred and the date of death, and

PS2
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 8 of 11

(3)
the representative has authority to act on behalf of the deceased beneficial owner;

·
if the beneficial interest in the Notes is held by a nominee or trustee of, custodian for, or other person in a similar

capacity to, the deceased beneficial owner, evidence satisfactory to Barclays Bank PLC from the nominee, trustee,
custodian or similar person attesting to the deceased's beneficial ownership of that Notes;

·
a written request for repayment signed by the authorized representative of the deceased beneficial owner with the
signature guaranteed by a firm that is a participant in the Security Transfer Agents Medallion Program, the New

York Stock Exchange Medallion Signature Program or the Stock Exchange Medallion Program (generally a
member of a registered national securities exchange, a member of the Financial Industry Regulatory Authority, or a
commercial bank or trust company having an office in the United States);

·
tax waivers and any other instruments or documents that Barclays Bank PLC reasonably requires in order to

establish the validity of the beneficial ownership of the Notes and the claimant's entitlement to payment; and

·
any additional information Barclays Bank PLC requires to evidence satisfaction of any conditions to the exercise of

the Survivor's Option or to document beneficial ownership or authority to make the election and to cause the
repayment of the Notes.
In turn, the broker or other entity will deliver each of these items, through the appropriate direct participant in DTC and the
facilities of DTC will deliver the Survivor's Option form of notice (the "Form of Notice"), to the trustee and to Barclays
Bank PLC and will certify to Barclays Bank PLC that the broker or other entity represents the deceased beneficial owner.
The broker or other entity will be responsible for disbursing payments received from the trustee, through the facilities of
DTC, to the authorized representative.
During any time in which the Notes are not represented by a global note and are issued in definitive form:

·
all references in this section to participants and DTC, including the DTC's governing rules, regulations and procedures,
will be deemed inapplicable;

·
all determinations that the DTC participants are required to make as described in this section will be made by Barclays
Bank PLC, including, without limitation, determining whether the applicable decedent is in fact the beneficial owner of
the interest in the Notes to be redeemed or is in fact deceased and whether the representative is duly authorized to
request redemption on behalf of the applicable beneficial owner; and

·
all redemption requests, to be effective, must:

·
be delivered by the representative to Barclays Bank PLC and to the trustee;

·
be made by completing the Form of Notice in accordance with the related instructions; and

·
be accompanied by, if applicable, a properly executed assignment or endorsement, in addition to all
documents that are otherwise required to accompany a redemption request. If the record holder of the

Note is a nominee of the deceased beneficial owner, a certificate or letter from the nominee attesting to
the deceased's ownership of a beneficial interest in the Note must also be delivered.
Barclays Bank PLC retains the right to limit the aggregate principal amount of Notes as to which exercises of the Survivor's
Option will be accepted from all authorized representatives of deceased beneficial owners and from the authorized
representative for any individual deceased beneficial owner in any one calendar year as described above. All other questions
regarding the eligibility or validity of any exercise of the Survivor's Option generally will be determined by Barclays Bank
PLC, which determination will be final and binding on all parties.
The Form of Notice may be obtained from Barclays Bank PLC, 745 Seventh Avenue, New York, NY 10019, Attention: US-
Syndicate, MTN Desk US, telephone: 212-412-1535.
UNITED STATES FEDERAL INCOME TAX TREATMENT
The following discussion supplements the discussion in the prospectus supplement under the heading "Certain U.S. Federal
Income Tax Considerations" and supersedes it to the extent inconsistent therewith. The following discussion (in conjunction
with the discussion in the prospectus supplement) summarizes certain of the material U.S. federal income tax consequences
of the purchase, beneficial ownership, and disposition of the Notes.
We intend to treat the Notes as indebtedness for U.S. federal income tax purposes and any reports to the Internal Revenue
Service (the "IRS") and U.S. holders will be consistent with such treatment, and each holder will agree to treat the Notes as
indebtedness for U.S. federal income tax purposes. The discussion that follows is based on this approach.

http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 9 of 11
PS3
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010

Pricing Supplement - USD 15 YR USMTN
Page 10 of 11
A U.S. holder will be taxable on interest income equal to the minimum coupon amount that will be paid on the Notes (the
"Minimum Coupon Amount") when it is accrued or received in accordance with the U.S. Holder's normal method of tax
accounting. The Notes will be treated as having "original issue discount" ("OID") for federal income tax purposes in an
amount equal to the excess of the aggregate interest payments on the Notes over the aggregate Minimum Coupon Amount of
the Notes, assuming they remain outstanding until their maturity. You will be required to include OID in income on a
constant yield basis during your ownership of the Notes. In the certain years, your taxable income in respect of the Notes will
exceed the cash interest payments you receive. See "U.S. Federal Income Tax Considerations--Original Issue Discount" in
the prospectus supplement.
3.8% Medicare Tax On "Net Investment Income"
Beginning in 2013, U.S. holders that are individuals, estates, and certain trusts will be subject to an additional 3.8% tax on all
or a portion of their "net investment income," which may include the interest payments and any gain realized with respect to
the Notes, to the extent of their net investment income that when added to their other modified adjusted gross income,
exceeds $200,000 for an unmarried individual, $250,000 for a married taxpayer filing a joint return (or a surviving spouse),
or $125,000 for a married individual filing a separate return. U.S. holders should consult their advisors with respect to their
consequences with respect to the 3.8% Medicare tax.
Information Reporting
Holders that are individuals (and, to the extent provided in future regulations, entities) may be subject to certain foreign
financial asset reporting obligations with respect to their Notes if the aggregate value of their Notes and their other "specified
foreign financial assets" exceeds $50,000. Significant penalties can apply if a holder fails to disclose its specified foreign
financial assets. This information reporting requirement is generally applicable for taxable years beginning after March 18,
2010. We urge you to consult your tax advisor with respect to this and other reporting obligations with respect to your Notes.
PROSPECTIVE PURCHASERS SHOULD CONSULT THEIR TAX ADVISORS AS TO THE FEDERAL, STATE,
LOCAL, AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION
OF NOTES.
CERTAIN EMPLOYEE RETIREMENT INCOME SECURITY ACT CONSIDERATIONS
Your purchase of a Note in an Individual Retirement Account (an "IRA"), will be deemed to be a representation and
warranty by you, as a fiduciary of the IRA and also on behalf of the IRA, that (i) neither the issuer, the placement agent nor
any of their respective affiliates has or exercises any discretionary authority or control or acts in a fiduciary capacity with
respect to the IRA assets used to purchase the Note or renders investment advice (within the meaning of Section 3(21)(A)(ii)
of the Employee Retirement Income Security Act ("ERISA")) with respect to any such IRA assets and (ii) in connection with
the purchase of the Note, the IRA will pay no more than "adequate consideration" (within the meaning of Section 408(b)(17)
of ERISA) and in connection with any redemption of the Note pursuant to its terms will receive at least adequate
consideration, and, in making the foregoing representations and warranties, you have (x) applied sound business principles in
determining whether fair market value will be paid, and (y) made such determination acting in good faith.
For additional ERISA considerations, see "Employee Retirement Income Security Act" in the prospectus supplement.
SUPPLEMENTAL PLAN OF DISTRIBUTION
We have agreed to sell to Barclays Capital Inc. (the "Agent"), and the Agent has agreed to purchase from us, the principal
amount of the Notes, and at the price, specified on the cover of this pricing supplement. The Agent is committed to take and
pay for all of the Notes, if any are taken.

PS4
http://sec.gov/Archives/edgar/data/312070/000119312510219715/d424b2.htm
9/30/2010